CN112645927A - 用于制备药物的方法 - Google Patents

用于制备药物的方法 Download PDF

Info

Publication number
CN112645927A
CN112645927A CN202011466648.XA CN202011466648A CN112645927A CN 112645927 A CN112645927 A CN 112645927A CN 202011466648 A CN202011466648 A CN 202011466648A CN 112645927 A CN112645927 A CN 112645927A
Authority
CN
China
Prior art keywords
chloro
solution
methyl
pyridin
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011466648.XA
Other languages
English (en)
Chinese (zh)
Inventor
J·林
A·奇斯佳科娃
W·顾
H·伊丁
J·李
X·令狐
P·迈耶
C·沙
J·斯塔尔茨
Y·王
H·张
J·张
T·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN112645927A publication Critical patent/CN112645927A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
CN202011466648.XA 2014-04-09 2015-04-08 用于制备药物的方法 Pending CN112645927A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014075011 2014-04-09
CNPCT/CN2014/075011 2014-04-09
CN201580029835.2A CN106659721B (zh) 2014-04-09 2015-04-08 用于制备药物的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580029835.2A Division CN106659721B (zh) 2014-04-09 2015-04-08 用于制备药物的方法

Publications (1)

Publication Number Publication Date
CN112645927A true CN112645927A (zh) 2021-04-13

Family

ID=54287327

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202011466648.XA Pending CN112645927A (zh) 2014-04-09 2015-04-08 用于制备药物的方法
CN201580029835.2A Active CN106659721B (zh) 2014-04-09 2015-04-08 用于制备药物的方法
CN202010547624.0A Active CN111777594B (zh) 2014-04-09 2015-04-08 用于制备药物的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201580029835.2A Active CN106659721B (zh) 2014-04-09 2015-04-08 用于制备药物的方法
CN202010547624.0A Active CN111777594B (zh) 2014-04-09 2015-04-08 用于制备药物的方法

Country Status (22)

Country Link
US (4) US20170022183A1 (enExample)
EP (2) EP3494971B1 (enExample)
JP (3) JP6723926B2 (enExample)
KR (3) KR20200038553A (enExample)
CN (3) CN112645927A (enExample)
AR (1) AR099989A1 (enExample)
AU (2) AU2015245743B2 (enExample)
BR (2) BR122020014933B8 (enExample)
CA (2) CA2945098C (enExample)
ES (1) ES2733495T3 (enExample)
HR (1) HRP20191306T1 (enExample)
IL (2) IL248205B (enExample)
MX (2) MX375638B (enExample)
MY (3) MY188526A (enExample)
NZ (1) NZ725450A (enExample)
PL (1) PL3129025T3 (enExample)
RU (1) RU2684102C2 (enExample)
SG (1) SG11201608421XA (enExample)
SI (1) SI3129025T1 (enExample)
TW (2) TWI678366B (enExample)
WO (1) WO2015154674A1 (enExample)
ZA (1) ZA201607066B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800282T1 (it) * 2012-03-01 2018-07-17 Genentech Inc Inibitori delle serina/treonina chinasi
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
UA120506C2 (uk) 2013-12-06 2019-12-26 Дженентек, Інк. Інгібітори серин/треонінкіназ
EP3494971B1 (en) 2014-04-09 2024-07-24 Genentech, Inc. Salts of erk inhibitors
CR20180316A (es) 2015-11-09 2018-10-05 Astrazeneca Ab Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
KR20180134347A (ko) 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
JP7530829B2 (ja) 2017-09-08 2024-08-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの診断及び治療方法
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
EP3546447A1 (en) * 2018-03-29 2019-10-02 Heidelberg Pharma GmbH Synthesis of (2s,3r,4r)-4,5-dihydroxyisoleucine and derivatives
WO2021110893A1 (en) * 2019-12-05 2021-06-10 Astrazeneca Ab Process and intermediates for the production of formula (i)
CN115710158A (zh) * 2021-08-23 2023-02-24 凯特立斯（深圳）科技有限公司 一种不对称催化制备替格瑞洛中间体的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1684954A (zh) * 2002-09-30 2005-10-19 万有制药株式会社 N－取代的－2－氧代二氢吡啶衍生物
CN101415681A (zh) * 2006-03-29 2009-04-22 弗·哈夫曼-拉罗切有限公司 作为mGluR2拮抗剂的吡啶和嘧啶衍生物
CN101902912A (zh) * 2007-11-06 2010-12-01 纳幕尔杜邦公司 杀真菌杂环胺
WO2013130976A1 (en) * 2012-03-01 2013-09-06 Array Biopharma Inc. Serine/threonine kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
US9867667B2 (en) * 2014-02-27 2018-01-16 Canon Usa Inc. Placement apparatus
EP3494971B1 (en) 2014-04-09 2024-07-24 Genentech, Inc. Salts of erk inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1684954A (zh) * 2002-09-30 2005-10-19 万有制药株式会社 N－取代的－2－氧代二氢吡啶衍生物
CN101415681A (zh) * 2006-03-29 2009-04-22 弗·哈夫曼-拉罗切有限公司 作为mGluR2拮抗剂的吡啶和嘧啶衍生物
CN101902912A (zh) * 2007-11-06 2010-12-01 纳幕尔杜邦公司 杀真菌杂环胺
WO2013130976A1 (en) * 2012-03-01 2013-09-06 Array Biopharma Inc. Serine/threonine kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GEORG MANOLIKAKES等: "Radical Catalysis of Kumada Cross-Coupling Reactions Using Functionalized Grignard Reagents", ANGEW. CHEM. INT. ED., vol. 48, pages 205 *

Also Published As

Publication number Publication date
JP2020114817A (ja) 2020-07-30
EP3129025A1 (en) 2017-02-15
EP3494971C0 (en) 2024-07-24
JP2021167321A (ja) 2021-10-21
CN106659721B (zh) 2021-01-01
TWI762806B (zh) 2022-05-01
ZA201607066B (en) 2018-05-30
CN106659721A (zh) 2017-05-10
HRP20191306T1 (hr) 2019-10-18
RU2684102C2 (ru) 2019-04-04
EP3494971B1 (en) 2024-07-24
AU2015245743A1 (en) 2016-10-27
CN111777594B (zh) 2023-06-27
BR122020014933B1 (pt) 2022-11-29
CA3167641A1 (en) 2015-10-15
TWI678366B (zh) 2019-12-01
MX2020010384A (es) 2022-05-19
JP6974524B2 (ja) 2021-12-01
MX2016013162A (es) 2017-04-27
BR112016023391A2 (enExample) 2017-08-15
US20180134685A1 (en) 2018-05-17
ES2733495T3 (es) 2019-11-29
NZ725450A (en) 2022-08-26
BR112016023391B1 (pt) 2022-08-09
JP6723926B2 (ja) 2020-07-15
RU2016139286A3 (enExample) 2018-10-26
US20200190061A1 (en) 2020-06-18
MX392460B (es) 2025-03-24
US10611753B2 (en) 2020-04-07
IL268690A (en) 2019-10-31
MY188526A (en) 2021-12-18
AU2020220208B2 (en) 2022-03-17
EP3129025A4 (en) 2018-01-17
JP2017510620A (ja) 2017-04-13
RU2016139286A (ru) 2018-05-15
KR20230006043A (ko) 2023-01-10
US11098028B2 (en) 2021-08-24
KR102490955B1 (ko) 2023-01-19
BR122020014933B8 (pt) 2022-12-13
BR112016023391A8 (pt) 2018-04-17
MY196320A (en) 2023-03-24
US11066389B2 (en) 2021-07-20
EP3494971A1 (en) 2019-06-12
US20170022183A1 (en) 2017-01-26
CA2945098A1 (en) 2015-10-15
IL248205B (en) 2019-09-26
AU2015245743B2 (en) 2020-09-24
EP3129025B1 (en) 2019-05-15
CA2945098C (en) 2022-10-04
WO2015154674A1 (en) 2015-10-15
MX375638B (es) 2025-03-06
AR099989A1 (es) 2016-08-31
PL3129025T3 (pl) 2019-11-29
TW201945358A (zh) 2019-12-01
KR20200038553A (ko) 2020-04-13
SG11201608421XA (en) 2016-11-29
CN111777594A (zh) 2020-10-16
TW201620897A (zh) 2016-06-16
IL248205A0 (en) 2016-11-30
US20190367484A1 (en) 2019-12-05
AU2020220208A1 (en) 2020-09-10
KR20160133566A (ko) 2016-11-22
MY198371A (en) 2023-08-28
SI3129025T1 (sl) 2019-08-30

Similar Documents

Publication Publication Date Title
CN106659721B (zh) 用于制备药物的方法
EP2781519B1 (en) Novel antiviral pyrrolopyridine derivative and a production method for same
KR20250031214A (ko) Prmt5 억제제 및 이의 용도
CN111542523A (zh) 作为prmt5抑制剂的杂环化合物
CN104136399B (zh) 泛素活化酶的吡唑并嘧啶基抑制剂
HK40039714A (en) Process for the manufacturing of medicaments
HK40039714B (zh) 用於制备药物的方法
HK40007970A (en) Salts of erk inhibitors
HK40007970B (en) Salts of erk inhibitors
NZ761260A (en) Crystalline salts of erk inhibitors
AU2023225437A1 (en) Indazole compound and pharmaceutical use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210413